Vijay Patil
Showed that very low-dose nivolumab added to cheap chemotherapy improves survival in head and neck cancer, a landmark for affordable immunotherapy.
Vijay Patil led the randomised trial of low-dose nivolumab (20 mg every 3 weeks) added to triple metronomic chemotherapy in advanced head and neck cancer, showing an overall survival benefit at a fraction of standard-dose cost.
| Title | Journal | Year |
|---|---|---|
| Low-dose immunotherapy in head and neck cancer: a randomized study | Journal of Clinical Oncology | 2023 |
Pages like this
not linked directly; found by shared links- PersonKumar Prabhash
Shares Confirm ultra-low-dose immunotherapy so it can be afforded where most patients live, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Head and neck squamous cell carcinoma.
- PersonRajendra Badwe
Shares Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre.
- IdeaCommunity health workers with smartphone AI screen for mouth cancer in South Asia
Shares Tata Memorial Centre, Head and neck squamous cell carcinoma.
- PersonVanita Noronha
Shares Tata Memorial Centre, Head and neck squamous cell carcinoma.
- TrialCheckMate 141
- PersonPankaj Chaturvedi
Shares Tata Memorial Centre, Head and neck squamous cell carcinoma.
- IdeaValidate low-cost metronomic oral regimens in phase 3 and carry them into guidelines
Shares Tata Memorial Centre, Head and neck squamous cell carcinoma.
- IdeaSubscription pricing for checkpoint inhibitors: fixed national fee, unlimited use
Shares Nivolumab, Immune checkpoint inhibitors.